11.04.15
Sterile manufacturing specialist Symbiosis Pharmaceutical Services has appointed Joanne Anderson as its new business development director to help drive its commercial growth.
The company has promoted Mrs. Anderson to the role following three successful years with the Scotland-based pharmaceutical contract manufacturing organization ( CMO ) and will join the management team.
Reporting to the chief executive officer, her responsibilities will include the strategic and operational management of all sales and marketing activities for Symbiosis globally.
A qualified analytical chemist with an MBA, Mrs. Anderson has worked in the Biopharmaceutical outsourcing sector for almost 15 years and has spent the last eight years specializing in the field of sterile injectable products for Clinical Trials and low volume commercial supply.
“Joanne has made a valuable contribution to the commercial team over the last few years in terms of generating market awareness of the services offered by Symbiosis and her professional approach to achieving significant year-on-year sales revenue growth,” said Colin MacKay, chief executive officer, Symbiosis Pharmaceutical Services. “As we look to further expand the business, it’s essential for us to have a management team comprising knowledgeable, high-performing and well-respected industry professionals in key senior roles. Our decision to appoint Joanne as our business development director aligns perfectly with that.”
Symbiosis recently announced plans to expand its sterile filling facility following increased demand for its small-scale sterile manufacturing services and to ensure continued Compliance with the latest interpretation of the guidelines by the MHRA .
“We are at a very important stage of the company’s development so I am delighted and honored to have been promoted into this new role to drive the commercial development of the company and take Symbiosis to the next level,” said Mrs. Anderson. “Recent investments into our facility enable us to aseptically manufacture and provide Lyophilization services at both the clinical stage and for clients with niche licensed products.”
Symbiosis specializes in the sterile fill/finish of Biologic and small molecule products into vials, which are either liquid or lyophilized formulations. The fast-growing CMO’s capabilities include the ability to handle and fill antibodies, proteins, peptides, Nucleic Acids , Cytotoxic , cytostatic and highly potent APIs including ADCs along with conventional small molecules.
The company has promoted Mrs. Anderson to the role following three successful years with the Scotland-based pharmaceutical contract manufacturing organization ( CMO ) and will join the management team.
Reporting to the chief executive officer, her responsibilities will include the strategic and operational management of all sales and marketing activities for Symbiosis globally.
A qualified analytical chemist with an MBA, Mrs. Anderson has worked in the Biopharmaceutical outsourcing sector for almost 15 years and has spent the last eight years specializing in the field of sterile injectable products for Clinical Trials and low volume commercial supply.
“Joanne has made a valuable contribution to the commercial team over the last few years in terms of generating market awareness of the services offered by Symbiosis and her professional approach to achieving significant year-on-year sales revenue growth,” said Colin MacKay, chief executive officer, Symbiosis Pharmaceutical Services. “As we look to further expand the business, it’s essential for us to have a management team comprising knowledgeable, high-performing and well-respected industry professionals in key senior roles. Our decision to appoint Joanne as our business development director aligns perfectly with that.”
Symbiosis recently announced plans to expand its sterile filling facility following increased demand for its small-scale sterile manufacturing services and to ensure continued Compliance with the latest interpretation of the guidelines by the MHRA .
“We are at a very important stage of the company’s development so I am delighted and honored to have been promoted into this new role to drive the commercial development of the company and take Symbiosis to the next level,” said Mrs. Anderson. “Recent investments into our facility enable us to aseptically manufacture and provide Lyophilization services at both the clinical stage and for clients with niche licensed products.”
Symbiosis specializes in the sterile fill/finish of Biologic and small molecule products into vials, which are either liquid or lyophilized formulations. The fast-growing CMO’s capabilities include the ability to handle and fill antibodies, proteins, peptides, Nucleic Acids , Cytotoxic , cytostatic and highly potent APIs including ADCs along with conventional small molecules.
